Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
Expert Opin Drug Metab Toxicol. 2016 Jun 21;
Authors: Wagenlehner FM, Alidjanov JF
INTRODUCTION: Urinary tract infections (UTIs) are the second most common nosocomially acquired infections, responsible for approximately 21% of healthcare-associated pyelonephritis and 10.5% of urosepsis. Worldwide overprescription of antimicrobials led to the emergence of multidrug-resistant uropathogens. Trends of increasing resistance resulted in the urgent need for novel antimicrobials which would be active against bacterial resistance mechanisms as an alternative to carbapenems, which are considered last resort antibiotics.
AREAS COVERED: The current review is based on a Medline search of published English language literature and contains summary information regarding a novel semisynthetic cephalosporin and β-lactamase inhibitor – ceftolozane + tazobactam and the evaluation of its pharmacologic properties, efficacy and safety in the indication of complicated UTIs (cUTIs) and activity against common bacterial resistance mechanisms.
EXPERT OPINION: In vivo and vitro studies demonstrated high activity of ceftolozane/tazobactam in the combination of 2:1 against a variety of uropathogens, including ESBL-producers and Pseudomonas aeruginosa. Phase II and Phase III studies performed in patients with cUTIs showed good tolerability and safety of ceftolozan/tazobactam when prescribed intravenously 1.5 g every 8 h for 7 days and at least non-inferiority to a high dose (750 mg) of levofloxacin. Pharmacokinetics of ceftolozane + tazobactam makes it worthy as an alternative for carbapenems in cases of cUTIs, also caused by multidrug resistant uropathogens.
PMID: 27327964 [PubMed – as supplied by publisher]